ADMA Biologics Inc (NASDAQ:ADMA) Expected to Post Earnings of -$0.22 Per Share

Share on StockTwits

Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to report earnings per share (EPS) of ($0.22) for the current quarter, according to Zacks. Five analysts have made estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.31) to ($0.11). ADMA Biologics reported earnings of ($0.33) per share during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The firm is scheduled to announce its next earnings results on Thursday, November 14th.

On average, analysts expect that ADMA Biologics will report full year earnings of ($0.92) per share for the current fiscal year, with EPS estimates ranging from ($1.14) to ($0.53). For the next financial year, analysts expect that the firm will report earnings of ($0.66) per share, with EPS estimates ranging from ($1.44) to ($0.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.04. The firm had revenue of $6.56 million during the quarter, compared to analyst estimates of $4.36 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.

A number of analysts recently commented on the company. BidaskClub lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Thursday, September 26th. Oppenheimer set a $14.00 price objective on ADMA Biologics and gave the stock a “buy” rating in a research report on Tuesday, June 25th. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. Dawson James lowered ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 target price for the company. in a research report on Monday, August 12th. Finally, Maxim Group restated a “buy” rating and set a $12.00 target price on shares of ADMA Biologics in a research report on Tuesday, August 27th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.20.

ADMA stock traded up $0.06 during midday trading on Friday, reaching $4.48. The stock had a trading volume of 426,500 shares, compared to its average volume of 905,347. The business has a fifty day simple moving average of $4.60 and a two-hundred day simple moving average of $4.27. The company has a quick ratio of 7.93, a current ratio of 10.26 and a debt-to-equity ratio of 1.79. The firm has a market cap of $260.12 million, a price-to-earnings ratio of -3.09 and a beta of 2.71. ADMA Biologics has a twelve month low of $2.08 and a twelve month high of $6.31.

Several institutional investors have recently bought and sold shares of ADMA. Perceptive Advisors LLC grew its position in shares of ADMA Biologics by 76.7% during the 2nd quarter. Perceptive Advisors LLC now owns 11,521,102 shares of the biotechnology company’s stock worth $44,586,000 after buying an additional 5,000,000 shares during the period. BlackRock Inc. grew its position in shares of ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock worth $7,343,000 after buying an additional 919,260 shares during the period. Vanguard Group Inc. grew its position in shares of ADMA Biologics by 47.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 786,567 shares during the period. Jefferies Group LLC acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $2,961,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,128,000. Institutional investors own 59.07% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: Support Level

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Oppenheimer Asset Management Inc. Raises Stock Position in Huntsman Co.
Oppenheimer Asset Management Inc. Raises Stock Position in Huntsman Co.
J Alexanders Holdings Inc  Shares Sold by Oppenheimer Asset Management Inc.
J Alexanders Holdings Inc Shares Sold by Oppenheimer Asset Management Inc.
14,600 Shares in KB Home  Acquired by Sumitomo Mitsui Trust Holdings Inc.
14,600 Shares in KB Home Acquired by Sumitomo Mitsui Trust Holdings Inc.
Sumitomo Mitsui Trust Holdings Inc. Makes New Investment in Taylor Morrison Home Corp
Sumitomo Mitsui Trust Holdings Inc. Makes New Investment in Taylor Morrison Home Corp
Gladstone Commercial Co.  Stake Raised by Sumitomo Mitsui Trust Holdings Inc.
Gladstone Commercial Co. Stake Raised by Sumitomo Mitsui Trust Holdings Inc.
31,900 Shares in Radian Group Inc  Purchased by Sumitomo Mitsui Trust Holdings Inc.
31,900 Shares in Radian Group Inc Purchased by Sumitomo Mitsui Trust Holdings Inc.


 
© 2006-2019 Zolmax.